CAJ | 학술논문

生长激素（GH）和胰岛素样生长因子Ⅰ（IGF-1）具有促进细胞有丝分裂和增殖的特性，对肿瘤的发生、发展具有显著的促进作用。血清 IGF-1水平可能与多种肿瘤的发生和增长相关。重组人生长激素（rhGH）在颅内肿瘤所致的生长激素缺乏症（GHD）患者中逐渐广泛应用，长期治疗是否会对肿瘤的复发或增大造成影响成为人们较为关注的问题。目前大部分临床观察和研究发现，rhGH 的治疗与颅内肿瘤的复发无相关性，不会增加肿瘤复发的风险。但仍需更长时间、更大人群的前瞻性研究证实。放射性治疗和残余肿瘤是颅内某些肿瘤复发的独立预测因素，在研究 GH治疗对肿瘤复发影响时需考虑此两项因素。本文将针对颅内肿瘤所致 GHD 患者使用 rhGH 是否会造成肿瘤复发或进展进行综述。
생장격소（GH）화이도소양생장인자Ⅰ（IGF-1）구유촉진세포유사분렬화증식적특성，대종류적발생、발전구유현저적촉진작용。혈청 IGF-1수평가능여다충종류적발생화증장상관。중조인생장격소（rhGH）재로내종류소치적생장격소결핍증（GHD）환자중축점엄범응용，장기치료시부회대종류적복발혹증대조성영향성위인문교위관주적문제。목전대부분림상관찰화연구발현，rhGH 적치료여로내종류적복발무상관성，불회증가종류복발적풍험。단잉수경장시간、경대인군적전첨성연구증실。방사성치료화잔여종류시로내모사종류복발적독립예측인소，재연구 GH치료대종류복발영향시수고필차량항인소。본문장침대로내종류소치 GHD 환자사용 rhGH 시부회조성종류복발혹진전진행종술。
With the introduction of recombinant growth hormone (GH) in 1985 there is an increasing interest in the GH replacement in adult GH deficiency (GHD). It can improve quality of life, bone mass and cardiovascular risk factors. But there are notable concerns about its mitogenic potential. GH and insulin-like growth factorⅠ (IGF-1) not only stimulate cell proliferation but also inhibit apoptosis. These mitogenic and antiapoptotic effects can have a profound impact on tumor growth. Whether long-term GH treatment will affect tumour recurrence or regrowth in the patients with GHD caused by the intracranial tumours, especially hypothalamo-pituitary tumours, or as a consequence of hypophysectomy or radiotherapy for their treatment attract more attention. At present, most studies of GH replacement therapy do not appear to demonstrate an increase in pituitary tumour recurrence, but conclusive evidence will only be generated by long-term randomized prospective clinical trials. Residual tumor and radiation therapy are independent prognostic factors for the recurrence of some intracranial tumor. The two factors should be taken into consideration when exploring the effects on tumor recurrence GH treatment effects on intracranial tumour recurrence. This paper reviewed the effect of using recombinant human GH on tumor recurrence in GHD patients caused by intracranial tumor.